Dr John Delaney | Executive Director, Amgen Biologics Discovery

Dr John Delaney, Executive Director, Amgen Biologics Discovery, Amgen

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary platform technology. John joined Amgen in 1992, is based at the Amgen San Francisco site, and leads research teams in numerous Amgen locations.  In 2010, John added the site leadership role for Amgen’s Burnaby, British Columbia research facility, managing the company’s significant protein science resources in Canada, and overseeing site administration.
John holds a Bachelor of Science in Zoology from the University of Montana and earned his Ph.D. in the Department of Microbiology at the University of Arizona. He completed his postdoctoral training at the University of Utah’s Department of Cellular, Viral, and Molecular Biology.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 14:55

Bi-Specific Antibodies: Discovery and Engineering

  • Strategies and challenges associated with bi-specific antibody discovery
  • Engineering strategies and formats for bi-specific antibodies
  • Challenges associated with production of bi-specific modalities

back to speakers